AstraZeneca

The U.S. clinical trials market is projected to reach $57.79 billion by 2030, driven by chronic disease prevalence and increased demand. Phase III trials dominated in 2024, with oncology leading by indication. Key players include IQVIA, Fortrea Inc., and PAREXEL International Corporation.

AstraZeneca's Phase III CAPItello-281 trial showed Truqap (capivasertib) + abiraterone + ADT improved rPFS in PTEN-deficient metastatic hormone-sensitive prostate cancer. Early OS signs also suggest benefit, with ongoing trial for further assessment. Truqap + Faslodex was approved in the EU for ER-positive, HER2-negative advanced breast cancer with PIK3CA, AKT1, or PTEN alterations.

Roche's Phase 3 trial SKYSCRAPER-01 showed tiragolumab did not improve survival in advanced lung cancer, failing to meet primary goals. Despite earlier promising data, final analysis indicated no sustained benefit. Roche will review tiragolumab's development, while other companies continue TIGIT drug research, hoping for breakthroughs.

SkyQuest projects the global personalized medicines market to reach USD 1352.81 Billion by 2031, with a CAGR of 11.40% driven by innovative therapies, partnerships, and advancements in genomics and AI-powered diagnostics. North America leads due to favorable regulatory frameworks and high R&D spending.

The U.S. clinical trials market is projected to grow to USD 57.79 billion by 2030, driven by chronic diseases and cancer prevalence. Phase III trials dominate due to their scale and cost. Oncology leads in indication, reflecting high cancer case numbers and R&D investment. Key players include IQVIA, PAREXEL, and Pfizer.

AstraZeneca terminated OUD drug AZD4041 development due to drug-drug interaction with antifungal itraconazole. Despite challenges, non-opioid medications are under development, but efficacy data is lacking. Opioid agonist therapies are expected to drive $1.75 billion in sales by 2033, reflecting patient preference and lack of alternatives. KOLs view OUD as a relapsing-remitting disorder, naturally inclined towards opioid use, making non-opioid treatments only adjunctive. The market lacks effective non-opioid therapies, but a strong profile could disrupt the OUD market.

Study finds states with higher economic vulnerability and minoritized populations have fewer gynecological cancer trials per 100,000 persons, highlighting the need for efforts to address these disparities.

The global antibody drug conjugate market is projected to grow from USD 7.72 billion to USD 23.3 billion by 2035, driven by advancements in antibody engineering and clinical trial successes. Over 280 ADCs are approved or in clinical studies, with 250+ in early development. Key segments include breast cancer, solid tumors, and HER-2 antigen. North America leads in market share, while Asia-Pacific shows higher growth potential.

Vivo, developed by OmniScience, won the CNS Summit Innovation Showcase for its ability to streamline clinical trial data accessibility and support actionable insights. The platform's genAI capabilities enable teams to make informed decisions, reducing trial timelines and increasing success rates.

AstraZeneca's CAPItello-281 phase 3 trial showed significant improvements in radiographic progression-free survival (rPFS) with Truqap (capivasertib) combined with Zytiga (abiraterone) and ADT in PTEN-deficient de novo metastatic hormone-sensitive prostate cancer patients, compared to Zytiga and ADT alone. The trial, involving over 1,000 patients, marks the first AKT inhibitor combination to demonstrate benefit in this specific form of prostate cancer, with ongoing assessment for overall survival.